{
    "clinical_study": {
        "@rank": "70622", 
        "arm_group": [
            {
                "arm_group_label": "Positive Expression", 
                "description": "Expression analysis:Positive expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51,SNF5, etc) in bladder cancer specimens."
            }, 
            {
                "arm_group_label": "Negative Expression", 
                "description": "Expression analysis:Negative expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51, SNF5,etc) in bladder cancer specimens."
            }
        ], 
        "biospec_descr": {
            "textblock": "bladder cancer specimens"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to try to figure out some bio-markers of chemosensitivity for\n      adjuvant chemotherapy for bladder cancer."
        }, 
        "brief_title": "Molecular Markers of Chemosensitivity for Bladder Cancer", 
        "completion_date": {
            "#text": "April 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Bladder Cancer", 
            "Effects of Chemotherapy"
        ], 
        "condition_browse": {
            "mesh_term": "Urinary Bladder Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Figure out some bio-markers of chemosensitivity for adjuvant chemotherapy for bladder\n      cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, 18 years of age or older, estimated life expectancy \u2265 6 months.\n\n          2. .Gone through standardize radical cystectomy and pelvic lymphadenectomy or\n             inoperable.\n\n          3. Transitional cell carcinoma of bladder, stage pT3N0M0,T2N1M0-T3-4N1-2M1.Transitional\n             cell carcinoma may be with or without squamous cell carcinoma and/or adenocarcinoma\n             components.\n\n          4. Electrocorticography(ECOG) performance status 0-2.\n\n          5. Blood routine:Absolute neutrophil count (ANC) \u2265 1500/\u03bcL,White blood cell count \u2265\n             3000/\u03bcLPlatelets \u2265 100,000/\u03bcL,Hemoglobin \u2265 10.0 g/dL,\n\n          6. Total serum bilirubin\u2264 1.5 x upper limit of normal (ULN).Serum aspartate transaminase\n             (AST; serum glutamic oxaloacetic transaminase(SGOT)) and serum alanine transaminase\n             (ALT; serum glutamic pyruvic transaminase (SGPT)) \u2264 2.5 x upper limit of normal\n             (ULN).\n\n          7. Creatinine clearance rate,Ccr \u2265 60%\n\n          8. ECG\uff1ano arrhythmias, no myocardial infarction. Signed and dated informed consent\n             document indicating that the patient (or legally acceptable representative) has been\n             informed of all pertinent aspects of the trial prior to enrollment.\n\n        Willingness and ability to comply with scheduled visits, treatment plans, laboratory\n        tests,and other study procedures.\n\n        Exclusion Criteria:\n\n          1. Past history of systemic chemotherapy\n\n          2. Serious heart and lung dysfunction.\n\n          3. Associated with central or peripheral neuropathy greater than 2 grade."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "1. The patients of locally advanced, recurrent, metastatic transitional cell carcinoma.\n\n          2. Gone through standardize radical cystectomy and pelvic lymphadenectomy or inoperable.\n\n          3. Experienced adjuvant chemotherapy(Gemcitabine and Cisplatin)."
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074241", 
            "org_study_id": "2012XLC02-2", 
            "secondary_id": "2012XLC02"
        }, 
        "intervention": {
            "arm_group_label": [
                "Positive Expression", 
                "Negative Expression"
            ], 
            "description": "Analysis of the expression of DNA repair genes (XPC, XPF, Brca1, Rad51,SNF5, etc.) in bladder cancer specimens.", 
            "intervention_name": "Expression analysis", 
            "intervention_type": "Other", 
            "other_name": "E-A"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chongqing", 
                    "country": "China", 
                    "state": "Chongqing", 
                    "zip": "400030"
                }, 
                "name": "Southwest hospital,Chian"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "2", 
        "official_title": "Molecular Markers of Chemosensitivity for Locally Advanced, Recurrent and Metastatic Bladder Cancer Based on the Adjuvant Chemotherapy of Gemcitabine and Cisplatin-a Prospective Control Study", 
        "overall_official": {
            "affiliation": "Southwest hospital", 
            "last_name": "Zhiwen Chen, M.D,Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "cancer progressive free survival rate", 
            "safety_issue": "Yes", 
            "time_frame": "60 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074241"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Southwest Hospital, China", 
            "investigator_full_name": "Zhiwen Chen", 
            "investigator_title": "M.D,Ph.D", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "60 months"
        }, 
        "source": "Southwest Hospital, China", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Southwest Hospital, China", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}